Accuray (ARAY) to Announce Quarterly Earnings on Wednesday

Accuray (NASDAQ:ARAY) is expected to be announcing its Q4 2026 results after the market closes on Wednesday, August 12th. Analysts expect Accuray to post earnings of ($0.03) per share and revenue of $105.30 million for the quarter. Individuals may visit the the company’s upcoming Q4 2026 earning report page for the latest details on the call scheduled for Wednesday, August 19, 2026 at 4:30 PM ET.

Accuray Stock Performance

Shares of NASDAQ ARAY opened at $0.29 on Tuesday. The company has a quick ratio of 0.66, a current ratio of 1.42 and a debt-to-equity ratio of 3.21. The firm’s 50-day moving average price is $0.29 and its two-hundred day moving average price is $0.41. Accuray has a 52-week low of $0.22 and a 52-week high of $2.10. The stock has a market capitalization of $34.78 million, a P/E ratio of -0.79 and a beta of 1.39.

Institutional Trading of Accuray

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC boosted its holdings in shares of Accuray by 762.3% in the first quarter. AQR Capital Management LLC now owns 162,922 shares of the medical equipment provider’s stock worth $292,000 after buying an additional 144,029 shares during the period. Jane Street Group LLC raised its holdings in shares of Accuray by 429.3% during the first quarter. Jane Street Group LLC now owns 91,944 shares of the medical equipment provider’s stock valued at $165,000 after acquiring an additional 74,574 shares during the period. Geode Capital Management LLC raised its holdings in shares of Accuray by 7.8% during the second quarter. Geode Capital Management LLC now owns 2,421,724 shares of the medical equipment provider’s stock valued at $3,318,000 after acquiring an additional 174,703 shares during the period. Marshall Wace LLP purchased a new stake in shares of Accuray in the 2nd quarter valued at approximately $820,000. Finally, Sei Investments Co. lifted its position in shares of Accuray by 83.0% in the 2nd quarter. Sei Investments Co. now owns 93,843 shares of the medical equipment provider’s stock valued at $129,000 after acquiring an additional 42,557 shares in the last quarter. 64.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have commented on ARAY shares. Jefferies Financial Group cut shares of Accuray from a “buy” rating to a “hold” rating in a research report on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Accuray in a report on Tuesday, August 4th. Finally, BTIG Research reiterated a “neutral” rating on shares of Accuray in a research report on Wednesday, July 8th. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $2.00.

About Accuray

Accuray Incorporated (NASDAQ: ARAY) is a global medical device company that develops, manufactures and markets innovative radiation therapy solutions for the treatment of cancer. The company’s flagship products include the CyberKnife® System, a robotic radiosurgery platform offering sub-millimeter precision, and the TomoTherapy® System, which combines helical computed tomography (CT) imaging with intensity-modulated radiation therapy (IMRT). More recently, Accuray introduced the Radixact® System, an advanced iteration of its TomoTherapy technology designed to enhance treatment speed and clinical workflow.

Accuray’s suite of products enables clinicians to deliver highly targeted radiation doses while minimizing exposure to surrounding healthy tissue.